Senior Management

Matthew F. McManus
Lilly Kong
Ted Myles
Daniel Bowman
Gary Riordan
Louis Hlousek
George Serbedzija

Matthew F. McManus, MD, PhD, MBA, President & CEO

Dr. Matthew McManus joined PrimeraDx in August 2010 from his prior position as Head of Cleveland Clinic Laboratories (CCL) and the Chief Operating Officer of the Pathology and Laboratory Medicine Institute.  In his three years in Cleveland, he successfully expanded the Clinic's reference laboratory services and secured funding for construction of a major new laboratory facility.  Prior to leading CCL, he was the Medical Scientist for the Novartis Institutes for Biomedical Research Drug Discovery Incubator, where he helped found the External Fast Follower group. He has also worked at McKinsey & Company, consulting for diagnostics, device and other health care clients, and at Procter & Gamble in sales and marketing. He received his MD and Ph.D. from the University of Pennsylvania School of Medicine, his MBA from Boston College, and his BA from the College of the Holy Cross.

Lilly Kong, D.V.M., Chief Scientific Officer

Dr. Lilly Kong joined PrimeraDx in early 2009. Prior to joining PrimeraDx, Dr. Kong served as the Vice President of Research and Development for Focus Diagnostics, a wholly owned subsidiary of Quest Diagnostics, where she was responsible for planning, initiating, directing and executing the scientific research and development effort with emphasis on both molecular and immunological diagnostic products and laboratory services.Dr. Kong is a veterinarian, virologist and molecular biologist by training, and has worked in the field of infectious disease diagnostics for the last 25 years. She recieved a D.V.M. from National Taiwan University, Taipei, Taiwan, an M.S. in Veterinary Microbiology from Auburn University, and had her postdoctoral fellowship training in Hematology at the University of Alabama, Birmingham.

Ted Myles, Chief Financial Officer

Mr. Ted Myles joined Primera, in November 2008, with more than 15 years of experience in financial and accounting roles in the Life Sciences industry. Mr. Myles most recently served as Senior Vice President of Finance and Chief Financial Officer for Pressure BioSciences, Inc., a Nasdaq-listed Life Sciences Tools company. Mr. Myles also served as the US controller for Merck KGaA, where he had a wide variety of responsibilities in the areas of accounting and business development. Prior to Merck KGaA, Ted worked in the health care investment banking group of SG Cowen Securities Corporation. Mr. Myles began his professional career at PriceWaterhouseCoopers, where he held positions of increasing responsibility between 1993 and 1997. Mr. Myles became a CPA in 1996, and earned a BSBA, with honors, in accounting and finance from the University of Hartford, and an MBA from Washington University in St. Louis. Mr. Myles also serves as a director and the treasurer for the School on Wheels of Massachusetts, a not-for-profit organization that is dedicated to providing educational services to children impacted by homelessness.

Daniel Bowman, Vice President of Sales and Marketing

Mr. Dan Bowman joined PrimeraDx in March of 2010, with more than 20 years of Sales and Marketing Management experience in the diagnostic market, the last ten years focused exclusively within early stage companies. Prior to joining PrimeraDx, Mr. Bowman was the Vice President of Global Commercial Operations at Osmetech Molecular Diagnostic where he was responsible for all aspects of commercial operations, culminating in the successful launch and commercialization of two FDA cleared systems. Mr. Bowman began his career at Abbott Laboratories Diagnostic Division and has held various senior management, sales and marketing positions within Gentra Systems, Applied Imaging and Idexx Laboratories. Mr. Bowman received his B.A. from California State University, Stanislaus and a M.A. from California State University, Chico.

Gary Riordan, Vice President Regulatory Affairs

Mr. Riordan joined PrimeraDX in June 2010 and has extensive regulatory experience, including serving as a primary reviewer at the U.S. Food and Drug Administration (FDA). He was the V.P. of Regulatory Affairs and Quality at Sequenom, from September 2008 to June 2010. Prior to joining Sequenom, Mr. Riordan worked at Ventana Medical Systems, and at Roche Molecular Systems, Inc. as Director, Regulatory Affairs. In these positions, he developed regulatory strategies and obtained many marketing authorizations. Mr. Riordan holds a B.A. in Molecular Biology, with a minor in Chemistry, from San Jose State University. He has co-authored numerous articles published in peer-reviewed journals, as well as abstracts and posters for scientific conferences.

Louis Hlousek, Vice President, Systems Development

Mr. Louis Hlousek joined PrimeraDx in 2008 with 25 years’ experience leading interdisciplinary teams in the development of commercial scientific and medical instrumentation systems. Most recently he was VP of Product Development at Ciphergen Biosystems, where he led a team of about 40 scientists and engineers in the development of a high-throughput SELDI mass spectrometry platform employed in proteomic translational medicine research. His experience spans that range of small start-ups to senior positions at large enterprises such as Thermo Instruments and Hewlett Packard, where he led the development of a variety of instruments and systems for research and clinical applications. A physicist by training, he’s a hands-on leader that favours elegant and simple solutions focused on exceeding customer expectation while streamlining development and manufacturing.

George Serbedzija, PhD, Vice President, Business Development

Dr. George Serbedzija joined PrimeraDx in 2008. Prior to joining PrimeraDx, Dr. Serbedzija served as Director of Business Development for Genzyme Genetics, a national reference laboratory focused on Oncology and Reproductive diagnostic testing and screening. Prior Genzyme Genetics, he held various management positions at CombinatoRx, Inc, first as head of the Infectious Disease program and then as Associate Director of Corporate Development. Dr. Serbedzija began his commercial career as a founding member of Phylonix, a Contract Research Organization providing in vivo assays for drug discovery and screening. He received his PhD in Developmental Neurobiology at the University of California, Irvine and a BS in Zoology at University of California, Davis.